Monoclonal antibody · developed by Hoffmann-La Roche
Prasinezumab (also known as RO7046015, PRX002, RG-7935) is administered by intravenous infusion in clinical trials in Parkinson's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07174310 | Phase 3 | Parkinson's Disease | Recruiting | PRTA |
| NCT03100149 | Phase 2 | Parkinson's Disease | Active not recruiting | PRTA |
| NCT02157714 | Phase 1 | Parkinson's Disease | Completed | PRTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Parkinson's Disease
Updated Oct 25, 2026.